Indications |
Parenteral Tuberculosis Adult: 1 g daily by deep IM or IV Inj for 2-4 mth, then 2-3 times per wk for the remainder of therapy. Max: 20 mg/kg/day. Child: and infants: 15-30 mg/kg daily. Max: 1 g/day. Renal impairment: Dose reduction may be needed. Special Populations: Renal impairment: Adjust dose based on creatinine clearance. |
Contraindications |
Hypersensitivity. |
Warnings / Precautions |
Renal impairment; when given with other anti-TB drugs, pregnancy, lactation, childn, ototoxicity, hypokalaemia. Audiometry and vestibular tests should be conducted at the start of and at regular intervals during treatment. |
Adverse Reactions |
Toxic nephritis, electrolyte disturbances resembling Bartter's syndrome may occur, hearing loss, tinnitus, vertigo, hepatic impairment, leukocytosis or leukopenia, urticaria, maculopapular skin rashes associated with febrile reactions, pain and bleeding at Injection site, sterile abscesses. |
Drug Interactions |
Co-admin with aminoglycosides may increase the risk of ototoxicity, resp paralysis and renal dysfunction. Increased risk of nephrotoxicity and ototoxicity with cisplatin and vancomycin. Concurrent colistin increases the risk of nephrotoxicity. See Below for More capreomycin Drug Interactions |
Mechanism of Actions |
Capreomycin is a cyclic polypeptide antimicrobial. It is bacteriostatic against various Mycobacteria, particularly those that have become resistant to primary anti-TB drugs. Absorption: Poor absorption from GI tract. Excretion: About 50% of a dose is removed unchanged by glomerular filtration within 12 hr. |
Storage Conditions |
Parenteral: Store at 15-30°C. |
ATC Classification |
J04AB30 - capreomycin ; Belongs to the class of antibiotics. Used in the systemic treatment of tuberculosis. |
Storage |
Parenteral: Store at 15-30°C. |
Available As |
|
Capreomycin
Post Review about Capreomycin Click here to cancel reply.
Capreomycin Containing Brands
Capreomycin is used in following diseases
Drug - Drug Interactions of Capreomycin
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.